Highlights

  • 1

    Review of the Phase III KEYNOTE-355 results in subgroup Analysis in untreated locally recurrent inoperable or mTNBC breast cancer.

  • 2

    Review of the KEYNOTE-522 Neoadjuvant Pembrolizumab + chemotherapy for early stage TNBC: Event-Free survival sensitivity and subgroup Analyses.

  • 3

    Review of the Management trends and outcomes assesment for inflammatory breast cancer

Summary

Phase III KEYNOTE-355 pembrolizumab + chemotherapy resulted in statistically and clinically meaningful improvements in PFS and OS vs chemotherapy alone for the first line treatment of PDL1 CPS ≥ 10 mTNBC. CPS ≥ 10 is a reasonable cut-off to define populations with metastatic TNBC expected to derive treatment benefit from pembrolizumab + chemotherapy.

These results provide further support for pembrolizumab + chemotherapy as a new standard of care regimen for patients with locally recurrent unresectable or mTNBC whose tumors expressed PD-L1(CPS ≥ 10) Phase III KEYNOTE-522 study, neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab resulted in statistically significant and clinically meaningful improvement in Event free survival (EFS). EFS sensitivity analyses show a robust treatment benefit of neoadjuvant pembrolizumab +chemotherapy followed by adjuvant pembrolizumab for previously untreated non-metastatic TNBC.

Results further support pembrolizumab + platinum-containing neoadjuvant chemotherapy, followed by adjuvant pembrolizumab after surgery, as new standard of care regimen for patients with high risk, early stage TNBC. The management trends and outcomes assessment for inflammatory breast cancer (IBC); patients with ER-/HER2- IBC continue to have poor outcomes and are a group in need of better systemic therapy options. Patient who underwent IR did not see an appreciable difference in RFS compared to their non-reconstructed counterparts. Patients should have consultation with plastic surgery as initial surgical management is being discussed if reconstruction is desired.

Comments (1)

  •
    Sean Mollitt

    excllent